Aduro Biotech is part of the healthcare sector and trades as part of the biotechnology industry. The company CEO is Stephen T. Isaacs. Aduro Biotech Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of therapies that transform the treatment of different diseases.
Previous Intraday Performance:
The ADRO shares had a previous change of 1.91% which opened at 3.14 and closed at 3.20. It moved to an intraday high of 3.22 and a low of 3.04.
Over the last five trading days, ADRO shares returned -1.23% and in the past 30 trading days it returned -12.81%. Over three months, it changed -17.10%. In one year it has changed -59.24% and within that year its 52 week high was 9.00 and its 52 week low was 2.34. ADRO stock is 36.75% above its 52 week low.
Our calculations result in a 200 day moving average of 4.23 and a 50 day moving average of 3.70. Right now, ADRO stock is trading -24.32% below its 200 day moving average and may not be a great opportunity to buy as it may continue to trend down.
The company has a market cap of $256.1m with 80.0m shares outstanding and a float of 78.5m shares. Trading volume was 289,398 shares and has experienced an average volume of 405,231 shares. Our calculation, using the current average volume and close price, leads me to believe that the liquidity is bad, highly speculative and an investor may want to avoid this stock.
The last annual reported EPS for Aduro Biotech was -1.21 which ended on 31st of December 2018. Based on 5 analyst estimates, the consensus EPS for the next quarter is -0.19.
Below was the last reported quarterly diluted earnings per share:
The long-term trend of the EPS is an important number as it indicates the present value of Aduro Biotech; it is usually expressed as a percentage and is then referred to as the EPS growth rate, which at this time is hard to estimate, but revenue growth has been -41.60% over the last twelve months.
Indicators Also to Watch:
Based on the latest filings, there is 58.90% of institutional ownership.
The beta was calculated to be 2.11.
Based on last reported financials, the company’s return on equity is -66.01%, return on assets is -26.27%, price-to-sales is 20.27 and price-to-book is 2.22.
Company Score Card:
Results are out of six:
4 : Growth Expectations Result
6 : Financial Safety Result
0 : Past Performance Result
1 : Valuation Result
0 : Dividend Safety Result
2 : Overall Result